(Q35040927)

6 August 2017

1 reference

title

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs (English)

1 reference

6 August 2017

0 references

Janyce F Rogers

1

1 reference

6 August 2017

Anne N Nafziger

series ordinal

2

1 reference

6 August 2017

Joseph S Bertino

series ordinal

3

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

American Journal of Medicine

6 August 2017

published in

1 reference

6 August 2017

volume

113

1 reference

6 August 2017

issue

9

1 reference

6 August 2017

page(s)

746-750

1 reference

How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Pharmacogenetics and psychopharmacotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Variability in drug metabolism: importance of genetic constitution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Clinical application of pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Relevance of genetic polymorphism in drug metabolism in the development of new drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Clinical pharmacogenomics: applications in pharmaceutical R&D

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Pharmacogenetics: a tool for individualizing antineoplastic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Opportunities and strategies for introducing pharmacogenetics into early drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Pharmacogenetics and adverse drug reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Interethnic differences of drug-metabolizing enzymes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901363-3

10.1016/S0002-9343(02)01363-3

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference